Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts
Daniel N. Kazdal, Volker Endris, Michael Allgäuer et al. · Journal of Thoracic Oncology · 2019
Cited by 96 works. doi:10.1016/j.jtho.2019.07.006 Open-access PDF
Authors
- Daniel N. Kazdal
- Volker Endris
- Michael Allgäuer
- Mark Kriegsmann
- Jonas Leichsenring
- Anna‐Lena Volckmar
- Alexander Harms
- Martina Kirchner
- Katharina Kriegsmann
- Olaf Neumann
- Regine Brandt
- Suranand B. Talla
- Eugen Rempel
- Carolin Ploeger
- Moritz von Winterfeld
- Petros Christopoulos
- Diana M. Merino
- Mark D. Stewart
- Jeff D. Allen
- Helge G. Bischoff
References
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Integrative genomics viewer
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- QuPath: Open source software for digital pathology image analysis
- The 2015 World Health Organization Classification of Lung Tumors
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma